Logo image of PASG

PASSAGE BIO INC (PASG) Stock Fundamental Analysis

NASDAQ:PASG - Nasdaq - US7027121000 - Common Stock - Currency: USD

5.74  -0.68 (-10.59%)

Fundamental Rating

2

Overall PASG gets a fundamental rating of 2 out of 10. We evaluated PASG against 553 industry peers in the Biotechnology industry. The financial health of PASG is average, but there are quite some concerns on its profitability. PASG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PASG has reported negative net income.
In the past year PASG has reported a negative cash flow from operations.
PASG had negative earnings in each of the past 5 years.
In the past 5 years PASG always reported negative operating cash flow.
PASG Yearly Net Income VS EBIT VS OCF VS FCFPASG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

PASG has a worse Return On Assets (-73.79%) than 65.64% of its industry peers.
PASG has a worse Return On Equity (-135.87%) than 60.22% of its industry peers.
Industry RankSector Rank
ROA -73.79%
ROE -135.87%
ROIC N/A
ROA(3y)-62.31%
ROA(5y)-54.67%
ROE(3y)-88.34%
ROE(5y)-72.01%
ROIC(3y)N/A
ROIC(5y)N/A
PASG Yearly ROA, ROE, ROICPASG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PASG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PASG Yearly Profit, Operating, Gross MarginsPASG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, PASG has more shares outstanding
PASG has more shares outstanding than it did 5 years ago.
PASG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PASG Yearly Shares OutstandingPASG Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PASG Yearly Total Debt VS Total AssetsPASG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

PASG has an Altman-Z score of -12.33. This is a bad value and indicates that PASG is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -12.33, PASG is not doing good in the industry: 77.58% of the companies in the same industry are doing better.
PASG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.33
ROIC/WACCN/A
WACCN/A
PASG Yearly LT Debt VS Equity VS FCFPASG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

PASG has a Current Ratio of 3.74. This indicates that PASG is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.74, PASG is in line with its industry, outperforming 43.22% of the companies in the same industry.
A Quick Ratio of 3.74 indicates that PASG has no problem at all paying its short term obligations.
With a Quick ratio value of 3.74, PASG perfoms like the industry average, outperforming 45.39% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.74
Quick Ratio 3.74
PASG Yearly Current Assets VS Current LiabilitesPASG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for PASG have decreased strongly by -525.49% in the last year.
EPS 1Y (TTM)-525.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1566.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PASG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.51% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y81.43%
EPS Next 2Y35.73%
EPS Next 3Y25.55%
EPS Next 5Y18.51%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PASG Yearly Revenue VS EstimatesPASG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
PASG Yearly EPS VS EstimatesPASG Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PASG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PASG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PASG Price Earnings VS Forward Price EarningsPASG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PASG Per share dataPASG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as PASG's earnings are expected to grow with 25.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.73%
EPS Next 3Y25.55%

More info and screens

0

5. Dividend

5.1 Amount

PASG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PASSAGE BIO INC

NASDAQ:PASG (8/1/2025, 8:00:02 PM)

5.74

-0.68 (-10.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners47.8%
Inst Owner Change0.02%
Ins Owners0.21%
Ins Owner Change0.04%
Market Cap17.91M
Analysts85.45
Price Target132.6 (2210.1%)
Short Float %N/A
Short Ratio0.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.34%
Min EPS beat(2)-6.56%
Max EPS beat(2)3.88%
EPS beat(4)2
Avg EPS beat(4)-4.26%
Min EPS beat(4)-32.14%
Max EPS beat(4)17.77%
EPS beat(8)5
Avg EPS beat(8)4%
EPS beat(12)8
Avg EPS beat(12)5.67%
EPS beat(16)10
Avg EPS beat(16)3.76%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2900.02%
PT rev (3m)1825.93%
EPS NQ rev (1m)-1900%
EPS NQ rev (3m)-1875.61%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.38
P/tB 0.38
EV/EBITDA N/A
EPS(TTM)-9.57
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-13.75
FCFYN/A
OCF(TTM)-13.74
OCFYN/A
SpS0
BVpS14.97
TBVpS14.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -73.79%
ROE -135.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.31%
ROA(5y)-54.67%
ROE(3y)-88.34%
ROE(5y)-72.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.74
Quick Ratio 3.74
Altman-Z -12.33
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)49.41%
Cap/Depr(5y)403.88%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-525.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1566.67%
EPS Next Y81.43%
EPS Next 2Y35.73%
EPS Next 3Y25.55%
EPS Next 5Y18.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y28.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.53%
EBIT Next 3Y6.96%
EBIT Next 5Y23.29%
FCF growth 1Y56.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.32%
OCF growth 3YN/A
OCF growth 5YN/A